Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the pivotal <a ...
